Patients with Duffy null status are more likely to experience misdiagnoses, unnecessary medical tests, and increased health ...
Kashiv BioSciences commercially launched Pexegra, a biosimilar referencing Neulasta, and Filra, a biosimilar referencing ...
The regulatory approval of the oral estrogen receptor antagonist is for patients whose cancer has an ESR1 mutation and has ...
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that the company’s CEO ...
MedPage Today on MSN
Ulcerative Colitis: Next Target for CAR T-Cell Therapy?
The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...
C4 Therapeutics' zinc finger protein-1 and 3 (IKZF1/3) degrader cemsidomide has demonstrated an overall response rate (ORR) ...
(OS) observed at 9 months; standard of care benchmark is ~47% -- 53% progression-free survival (PFS) observed at 9 months; ...
A team from the universities of Umeå and Ghent has discovered that neutrophils carefully control zinc levels to weaken and ...
The ongoing policy debate about pharmaceutical and biologic patents has been coopted by those who don’t like ...
KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses – – Consistent activity across pre-specified subgroups, ...
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the ...
Cisplatin-based neoadjuvant chemotherapy typically improves outcomes for patients with muscle-invasive bladder cancer, but not all groups benefit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback